›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:SOPHiA DDM Dx RNAtarget Oncology Solution
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sophia GeneticsType:
CE Marked
Related tests:
The CE-IVD marked SOPHiA DDM Dx RNAtarget Oncology Solution accurately detects novel (partner-agnostic) fusions in 11 driver genes and exon-skipping
events in EGFR and MET, even with minimal RNA sample input. The solution is expertly designed to detect fusion and exon-skipping events with high diagnostic sensitivity and specificity, delivering clinical-grade analytical performance.
Cancer:
Lung Cancer
Gene:
ALK (Anaplastic lymphoma kinase), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4)
See More ...
ALK (Anaplastic lymphoma kinase), EGFR (Epidermal growth factor receptor), FGFR1 (Fibroblast growth factor receptor 1), FGFR2 (Fibroblast growth factor receptor 2), FGFR3 (Fibroblast growth factor receptor 3), FGFR4 (Fibroblast growth factor receptor 4), MET (MET proto-oncogene, receptor tyrosine kinase), NRG1 (Neuregulin 1), NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1), NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2), NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
Method:
Next-Generation Sequencing (NGS)
